MX2021006695A - Moduladores de trex1. - Google Patents

Moduladores de trex1.

Info

Publication number
MX2021006695A
MX2021006695A MX2021006695A MX2021006695A MX2021006695A MX 2021006695 A MX2021006695 A MX 2021006695A MX 2021006695 A MX2021006695 A MX 2021006695A MX 2021006695 A MX2021006695 A MX 2021006695A MX 2021006695 A MX2021006695 A MX 2021006695A
Authority
MX
Mexico
Prior art keywords
trex1
modulators
compositons
treating
compounds
Prior art date
Application number
MX2021006695A
Other languages
English (en)
Inventor
Victor S Gehling
Anna Gardberg
Jonathan E Wilson
Avinash Khanna
Julian R Levell
Kennedy Taveras
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of MX2021006695A publication Critical patent/MX2021006695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplifiers (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Burglar Alarm Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de la Fórmula (I): (VER FORMULA I); y sales farmacéuticamente aceptables y composiciones de estos que son útiles para tratar una variedad de afecciones asociadas con TREX1.
MX2021006695A 2018-12-06 2019-12-06 Moduladores de trex1. MX2021006695A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776031P 2018-12-06 2018-12-06
PCT/US2019/064825 WO2020118133A1 (en) 2018-12-06 2019-12-06 Modulators of trex1

Publications (1)

Publication Number Publication Date
MX2021006695A true MX2021006695A (es) 2021-09-23

Family

ID=69024702

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006695A MX2021006695A (es) 2018-12-06 2019-12-06 Moduladores de trex1.

Country Status (28)

Country Link
US (1) US20220017502A1 (es)
EP (1) EP3891145B1 (es)
JP (1) JP7471297B2 (es)
KR (1) KR20210102310A (es)
CN (1) CN113396149A (es)
AU (1) AU2019395005A1 (es)
BR (1) BR112021010919A2 (es)
CA (1) CA3122093A1 (es)
CL (1) CL2021001461A1 (es)
CO (1) CO2021008816A2 (es)
CY (1) CY1126082T1 (es)
DK (1) DK3891145T3 (es)
EA (1) EA202191519A1 (es)
ES (1) ES2949999T3 (es)
FI (1) FI3891145T3 (es)
HR (1) HRP20230701T1 (es)
HU (1) HUE062866T2 (es)
IL (1) IL283672A (es)
LT (1) LT3891145T (es)
MA (1) MA54386B1 (es)
MX (1) MX2021006695A (es)
PE (1) PE20212070A1 (es)
PL (1) PL3891145T3 (es)
PT (1) PT3891145T (es)
RS (1) RS64336B1 (es)
SG (1) SG11202105772SA (es)
SI (1) SI3891145T1 (es)
WO (1) WO2020118133A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020316056A1 (en) * 2019-07-23 2022-02-03 Constellation Pharmaceuticals, Inc. Modulators of TREX1
WO2022031640A1 (en) * 2020-08-04 2022-02-10 Wake Forest University Health Sciences Trex1 inhibitors and uses thereof
CR20230542A (es) * 2021-04-26 2024-03-19 Constellation Pharmaceuticals Inc Moduladores de trex1
IL308220A (en) * 2021-05-05 2024-01-01 Constellation Pharmaceuticals Inc Modulators of TREX1
WO2023137030A1 (en) * 2022-01-11 2023-07-20 Constellation Pharmaceuticals, Inc. Modulators of trex1
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
WO2023250439A1 (en) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056124A2 (en) * 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
WO2009106561A1 (en) * 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009147079A1 (en) * 2008-06-02 2009-12-10 Janssen Pharmaceutica Nv 3,4-dihydropyrimidine trpa1 antagonists
BR112012007349A2 (pt) * 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
WO2011107494A1 (de) * 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012125887A1 (en) * 2011-03-17 2012-09-20 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
CN113396149A (zh) 2021-09-14
HUE062866T2 (hu) 2023-12-28
PT3891145T (pt) 2023-07-18
PL3891145T3 (pl) 2023-08-07
HRP20230701T1 (hr) 2023-10-13
EA202191519A1 (ru) 2021-10-27
JP7471297B2 (ja) 2024-04-19
MA54386A (fr) 2021-10-13
WO2020118133A1 (en) 2020-06-11
AU2019395005A1 (en) 2021-06-17
ES2949999T3 (es) 2023-10-04
PE20212070A1 (es) 2021-10-26
DK3891145T3 (da) 2023-07-24
EP3891145A1 (en) 2021-10-13
EP3891145B1 (en) 2023-04-12
JP2022510431A (ja) 2022-01-26
CL2021001461A1 (es) 2021-12-17
SI3891145T1 (sl) 2023-11-30
CO2021008816A2 (es) 2021-07-19
CA3122093A1 (en) 2020-06-11
SG11202105772SA (en) 2021-06-29
KR20210102310A (ko) 2021-08-19
CY1126082T1 (el) 2023-11-15
US20220017502A1 (en) 2022-01-20
IL283672A (en) 2021-07-29
RS64336B1 (sr) 2023-08-31
LT3891145T (lt) 2023-08-10
BR112021010919A2 (pt) 2021-08-24
FI3891145T3 (fi) 2023-07-18
MA54386B1 (fr) 2023-08-31

Similar Documents

Publication Publication Date Title
MX2021006695A (es) Moduladores de trex1.
JOP20220142A1 (ar) مثبطات kras g12c
JOP20200011A1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
MX2018010192A (es) Inhibidores de glucosidasa.
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PH12018500065A1 (en) Oxysterols and methods of use thereof
ZA201701299B (en) Glycosidase inhibitors
PH12017501326A1 (en) Tgf-� inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2018010191A (es) Inhibidores de glucosidasa.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
CR20210235A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
MX2016013564A (es) Inhibidores heterociclicos de cinasas.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2021013531A (es) Inhibidores de cdk.
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021003686A (es) Medicamento para el tratamiento de la tos cronica.
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
WO2018039077A8 (en) Therapeutic compounds
MY193239A (en) Novel b-lactamase inhibitors